Gilead Sciences Inc. (GILD) is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India,Indonesia, and Pakistan. Read More
The U.K. agency that evaluates the cost effectiveness of prescription drugs has recommended the government pay for the controversial Sovaldi hepatitis C treatment, although not for all patients. Read More
A new analysis finds that half of all generic drugs sold through retailers became more expensive over the past 12 months. In fact, the prices paid by pharmacies more than doubled for one out of 11 generics. Read More
In The Wall Street Journal, AHIP President and CEO Karen Ignagni writes that… Read More
How much can we afford to pay for one drug? How much profit does one company… Read More
A new drug for the liver disease hepatitis C is scaring people. Read More
“The fundamental concern is Sovaldi and other speciality drugs are going… Read More
Statement from the National Coalition on Health Care’s President and CEO… Read More
Gilead Sciences’ new hepatitis C drug receives as much praise for its… Read More
Gilead Sciences’ controversial $1,000-a-day Sovaldi pill is priced in line… Read More
There is one other way that Kalydeco is an excellent example of personalized… Read More
1. It’s all about price — even when it’s not: Even before Foster… Read More